SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter H. Proctor who wrote (358)5/3/1998 11:47:00 AM
From: VultureInvest  Read Replies (2) of 670
 
No dilution for acquisition

Looking over the deal, their does not appear to be any dilution from the purchase of Humantech.
1. The deal for firstly $1.5 million in cash. I bet the growth in revenues in one year will outpace this figure. Also, the use of 1.5 million shares in addition to cash doesn't have much impact on present dilution conditions as the company still maintains loss. In fact the loss per share will be lower.

2. Goodwill along with added sales channels should potentially contribute to book value along with any gains in sales over the next 4 quarters.

3. Humantech owners probably viewed a company like PRCY as being more favorable a purchaser than a larger corporate play (i.e, Johnson&Johnson, Merck, etc)since upside potential can be more significant.

4. The company still has approx $9 million in cash? This, perhaps, represents more purchasing power than one might expect.

Go Procyte!!!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext